Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00540605 · ClinicalTrials.gov registry record · Phase 1

Blood Levels of Tenofovir Gel in HIV Uninfected Pregnant Women Planning Cesarean Delivery

A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
21
Enrollment target
1
Study location

NCT00540605 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 21 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00540605, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

A new approach to HIV prevention currently being studied includes the use of topical microbicides, substances that kill microbes. The purpose of this study is to determine the levels of tenofovir, a microbicide in gel form, in HIV uninfected pregnant women who are expecting to deliver by cesarean.

Conditions Studied

Interventions

  • DRUG Tenofovir 1% vaginal gel

Study Locations (1)

Pennsylvania

  • Pitt CRS - Pittsburgh

Trial Details

FieldValue
Enrollment Target 21 participants
Est. Completion 2010-01
Phase Phase 1

What the Registry Record Tells You About NCT00540605

The ClinicalTrials.gov registry entry for NCT00540605 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (95% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Tenofovir 1% vaginal gel is the first listed.

NCT00540605 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00540605 about?

NCT00540605 is a clinical study titled "Blood Levels of Tenofovir Gel in HIV Uninfected Pregnant Women Planning Cesarean Delivery". A new approach to HIV prevention currently being studied includes the use of topical microbicides, substances that kill microbes. The purpose of this study is to determine the levels of tenofovir, a microbicide in gel form, in HIV uninfected pregnant women who are expecting to deliver by cesarean.

What is the current status of trial NCT00540605?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. Estimated completion is 2010-01.

What conditions does trial NCT00540605 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00540605?

The interventions under investigation include: Tenofovir 1% vaginal gel (DRUG).

Who is sponsoring clinical trial NCT00540605?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00540605 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.